Aditxt (ADTX) announced that its acquisition target, Evofem Biosciences (EVFM), has secured voting agreements with certain of its investors to ensure they will vote in favor of the merger proposal at Evofem’s upcoming Special Meeting of Stockholders.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADTX:
- Aditxt, Inc. Focuses on Growth Amid Nasdaq Compliance
- Aditxt announces ‘positive’ FDA feedback for Appili Therapeutics ATI-1801
- Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements
- Aditxt Enters Major Investment Agreement with Evofem
- Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy